Advanced search
Publication Cover
Expert Review of Dermatology Volume 8, 2013 - Issue 3
Journal homepage
18
Views
4
CrossRef citations to date
0
Altmetric
Review

Current update on the treatment of genital warts

Valerie R Yanofsky Albert Einstein College of Medicine, Bronx, New York, NY, USA; Albert Einstein College of Medicine, Bronx, New York, NY, USA
,
Rita V Linkner Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, 5th Floor, New York, NY 10029, USA; Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, 5th Floor, New York, NY 10029, USA
,
David Pompei Albert Einstein College of Medicine, Bronx, New York, NY, USA; Albert Einstein College of Medicine, Bronx, New York, NY, USA
&
Gary Goldenberg Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, 5th Floor, New York, NY 10029, USA. [email protected]; Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, 5th Floor, New York, NY 10029, USA. [email protected]
Pages 321-332 | Published online: 10 Jan 2014

References

  • Fleischer AB Jr, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex. Transm. Dis. 28(11), 643–647 (2001).
  • Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex. Transm. Dis. 26(4 Suppl.), S2–S7 (1999).
  • Batista CS, Attallah AN, Saconato H et al. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst. Rev. 4, CD006562 (2010).
  • Garland SM, Steben M, Sings HL et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 199(6), 805–814 (2009).
  • Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-2), 1–24 (2007).
  • Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J. Am. Acad. Dermatol. 43(1 Pt 2), S18–S26 (2000).
  • Lombard I, Vincent-Salomon A, Validire P et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J. Clin. Oncol. 16(8), 2613–2619 (1998).
  • Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J. Clin. Microbiol. 37(10), 3316–3322 (1999).
  • Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10, 122–163 (1988).
  • Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N. Engl. J. Med. 348(6), 489–490 (2003).
  • Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm. Rep. 55(RR-11), 1–94 (2006).
  • Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol. Online J. 12(3), 5 (2006).
  • Mougin C, Dalstein V, Prétet JL, Gay C, Schaal JP, Riethmuller D. [Epidemiology of cervical papillomavirus infections. Recent knowledge]. Presse Med. 30(20), 1017–1023 (2001).
  • Sanclemente G, Gill DK. Human papillomavirus molecular biology and pathogenesis. J. Eur. Acad. Dermatol. Venereol. 16(3), 231–240 (2002).
  • Jenkins D, Tay SK, McCance DJ, Campion MJ, Clarkson PK, Singer A. Histological and immunocytochemical study of cervical intraepithelial neoplasia (CIN) with associated HPV 6 and HPV 16 infections. J. Clin. Pathol. 39(11), 1177–1180 (1986).
  • McDougall JK, Beckmann AM, Kiviat NB. Methods for diagnosing papillomavirus infection. Ciba Found. Symp. 120, 86–103 (1986).
  • Pirog EC, Chen YT, Isacson C. MIB-1 immunostaining is a beneficial adjunct test for accurate diagnosis of vulvar condyloma acuminatum. Am. J. Surg. Pathol. 24(10), 1393–1399 (2000).
  • Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157(3), 218–226 (2003).
  • Baken LA, Koutsky LA, Kuypers J et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J. Infect. Dis. 171(2), 429–432 (1995).
  • Oriel JD. Natural history of genital warts. Br. J. Vener. Dis. 47(1), 1–13 (1971).
  • Burk RD, Kelly P, Feldman J et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex. Transm. Dis. 23(4), 333–341 (1996).
  • Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338(7), 423–428 (1998).
  • Coleman N, Birley HD, Renton AM et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102(6), 768–774 (1994).
  • Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77(1), 121–127 (1996).
  • Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos F et al. High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann. Surg. Oncol. 15(5), 1470–1475 (2008).
  • Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am. J. Dermatopathol. 31(6), 561–573 (2009).
  • Schwartz RA. Verrucous carcinoma of the skin and mucosa. J. Am. Acad. Dermatol. 32(1), 1–21; quiz 22 (1995).
  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6), 1129–1136 (1990).
  • Brownstein MH, Shapiro L. Verrucous carcinoma of skin: epithelioma cuniculatum plantare. Cancer 38(4), 1710–1716 (1976).
  • Batsakis JG, Hybels R, Crissman JD, Rice DH. The pathology of head and neck tumors: verrucous carcinoma, Part 15. Head Neck Surg. 5(1), 29–38 (1982).
  • Drachenberg CB, Blanchaert R, Ioffe OB, Ord RA, Papadimitriou JC. Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bcl-2, p53, and Her-2/neu, and indexes of cell turnover. Cancer Detect. Prev. 21(6), 483–489 (1997).
  • Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J. Infect. Dis. 205(10), 1544–1553 (2012).
  • Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol. Oncol. 117(2 Suppl.), S5–S10 (2010).
  • Maden C, Sherman KJ, Beckmann AM et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J. Natl Cancer Inst. 85(1), 19–24 (1993).
  • Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts). Australas. J. Dermatol. 39(Suppl. 1), S2–S4 (1998).
  • US Department of Health and Human Services. Acute pain management: operative or medical procedures and trauma Publication No 92-0023. Clinical Practice Guidelines No 11998.
  • von Krogh K. Podophyllotoxin for condyloma acuminata eradication. Clinical and experimental comparative studies on Podophyllum lignans, colchicine, and 5-fluorouracil. Acta Dermatolvenereol. 98, 31–48 (1991).
  • Mohanty KC. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int. J. STD AIDS 5(4), 253–256 (1994).
  • Lacey CJ, Goodall RL, Tennvall GR et al.; Perstop Pharma Genital Warts Clinical Trial Group. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex. Transm. Infect. 79(4), 270–275 (2003).
  • Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet. Gynecol. 77(5), 735–739 (1991).
  • Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin. Med. 64(4), 263–265 (1988).
  • Beutner KR, Wiley DJ, Douglas JM et al. Genital warts and their treatment. Clin. Infect. Dis. 28(Suppl. 1), S37–S56 (1999).
  • Wiley DJ, Douglas J, Beutner K et al. External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. 35(Suppl. 2), S210–S224 (2002).
  • Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs 58(2), 375–390 (1999).
  • Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200 (2002).
  • Bilu D, Sauder DN. Imiquimod: modes of action. Br. J. Dermatol. 149(Suppl. 66), 5–8 (2003).
  • Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex. Transm. Dis. 30(2), 124–128 (2003).
  • Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp. Biol. Med. (Maywood) 233(8), 968–979 (2008).
  • Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 67(15), 2187–2210 (2007).
  • Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human papillomavirus. Arch. Dermatol. 134(1), 25–30 (1998).
  • Gollnick H, Barasso R, Jappe U et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int. J. STD AIDS 12(1), 22–28 (2001).
  • Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am. J. Obstet. Gynecol. 200(3), 233.e1–7 (2009).
  • Ahn WS, Yoo J, Huh SW et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 12(5), 383–390 (2003).
  • Sutherland BA, Rahman RM, Appleton I. Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J. Nutr. Biochem. 17(5), 291–306 (2006).
  • Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex. Transm. Dis. 20(6), 344–345 (1993).
  • Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin. Med. 63(6), 390–392 (1987).
  • Taner ZM, Taskiran C, Onan AM, Gursoy R, Himmetoglu O. Therapeutic value of trichloroacetic acid in the treatment of isolated genital warts on the external female genitalia. J. Reprod. Med. 52(6), 521–525 (2007).
  • Kodner CM, Nasraty S. Management of genital warts. Am. Fam. Physician 70(12), 2335–2342 (2004).
  • Simmons PD, Langlet F, Thin RN. Cryotherapy versus electrocautery in the treatment of genital warts. Br. J. Vener. Dis. 57(4), 273–274 (1981).
  • Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon α 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin. Med. 67(4), 297–302 (1991).
  • Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin. Med. 66(1), 16–19 (1990).
  • Scoular A. Choosing equipment for treating genital warts in genitourinary medicine clinics. Genitourin. Med. 67(5), 413–419 (1991).
  • Duus BR, Philipsen T, Christensen JD, Lundvall F, Søndergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin. Med. 61(1), 59–61 (1985).
  • Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology (Williston Park, NY) 19(9), 1165–1171; discussion 1171 (2005).
  • Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in CO2 laser-generated plume of smoke and its consequences to the surgeon. Obstet. Gynecol. 75(1), 114–118 (1990).
  • Carrozza PM, Merlani GM, Burg G, Hafner J. CO(2) laser surgery for extensive, cauliflower-like anogenital condylomata acuminata: retrospective long-term study on 19 HIV-positive and 45 HIV-negative men. Dermatology (Basel) 205(3), 255–259 (2002).
  • von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A; European Course on HPV Associated Pathology (ECHPV); European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of anogenital warts. Int. J. STD AIDS 12(Suppl. 3), 40–47 (2001).
  • Greene I. Therapy for genital warts. Dermatol. Clin. 10(1), 253–267 (1992).
  • von Krogh G, Longstaff E. Podophyllin office therapy against condyloma should be abandoned. Sex. Transm. Infect. 77(6), 409–412 (2001).
  • von Krogh G. The benefician effect of 1% 5-FU in 70% ethanol on therapeutically refractory condylomas in the preputial cavity. Sex Transm. Dis. 5, 137–140 (1978).
  • Dyment PG. Human papillomavirus infection. Adolesc. Med. 7(1), 119–130 (1996).
  • Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330–338 (2003).
  • Wein AJ, Benson GS. Treatment of urethral condyloma acuminatum with 5-fluorouracil cream. Urology 9(4), 413–415 (1977).
  • Yang J, Pu YG, Zeng ZM, Yu ZJ, Huang N, Deng QW. Interferon for the treatment of genital warts: a systematic review. BMC Infect. Dis. 9, 156 (2009).
  • Petersen CS, Bjerring P, Larsen J et al. Systemic interferon α-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin. Med. 67(2), 99–102 (1991).
  • Vance JC, Bart BJ, Hansen RC et al. Intralesional recombinant α-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch. Dermatol. 122(3), 272–277 (1986).
  • Douglas JM Jr, Eron LJ, Judson FN et al. A randomized trial of combination therapy with intralesional interferon α 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J. Infect. Dis. 162(1), 52–59 (1990).
  • De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 124(7), 1626–1636 (2009).
  • Garland SM, Hernandez-Avila M, Wheeler CM et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928–1943 (2007).
  • Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574), 1693–1702 (2007).
  • Schwartz JL. HPV vaccination’s second act: promotion, competition, and compulsion. Am. J. Public Health 100(10), 1841–1844 (2010).
  • Smit EF. [New data presented at ASCO 2002 concerning small cell bronchial cancer]. Rev. Pneumol. Clin. 58(5 Pt 2), 3S11–3S14 (2002).
  • Einstein MH, Baron M, Levin MJ et al.; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccin. 5(10), 705–719 (2009).
  • Dillner J, Kjaer SK, Wheeler CM et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, c3493 (2010).
  • Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int. J. Infect. Dis. 11(Suppl. 2), S17–S25 (2007).
  • Castle PE, Scarinci I. Should HPV vaccine be given to men? BMJ 339, b4127 (2009).
  • Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365(17), 1576–1585 (2011).
  • Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 364(5), 401–411 (2011).
  • Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339, b3884 (2009).
  • Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect. Dis. 11(1), 39–44 (2011).
  • Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex. Transm. Infect. 87(7), 544–547 (2011).
  • Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. NZ Med. J. 124(1339), 51–58 (2011).
  • Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am. J. Public Health 102(5), 833–835 (2012).
  • Joura EA, Garland SM, Paavonen J et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344, e1401 (2012).
  • Saslow D, Castle PE, Cox JT et al.; Gynecologic Cancer Advisory Group. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57(1), 7–28 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.